Zacks: Analysts Anticipate Synlogic Inc (SYBX) to Post -$0.55 EPS

Share on StockTwits

Wall Street brokerages expect Synlogic Inc (NASDAQ:SYBX) to announce earnings per share (EPS) of ($0.55) for the current quarter, Zacks reports. Five analysts have issued estimates for Synlogic’s earnings, with the lowest EPS estimate coming in at ($0.66) and the highest estimate coming in at ($0.44). Synlogic reported earnings of ($0.59) per share during the same quarter last year, which indicates a positive year over year growth rate of 6.8%. The firm is scheduled to report its next earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Synlogic will report full year earnings of ($2.28) per share for the current year, with EPS estimates ranging from ($2.65) to ($1.93). For the next financial year, analysts forecast that the company will report earnings of ($2.50) per share, with EPS estimates ranging from ($2.93) to ($1.91). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Synlogic.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.51) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.03. Synlogic had a negative return on equity of 38.93% and a negative net margin of 2,005.43%. The business had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.42 million.

A number of equities analysts have recently commented on the company. Zacks Investment Research downgraded Synlogic from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of Synlogic in a research report on Tuesday, March 12th. BTIG Research began coverage on Synlogic in a report on Tuesday, February 12th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Jefferies Financial Group began coverage on Synlogic in a report on Tuesday, April 30th. They issued a “buy” rating and a $18.00 price target for the company. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $18.84.

Shares of Synlogic stock traded down $0.37 on Thursday, reaching $8.20. 34,205 shares of the company were exchanged, compared to its average volume of 63,575. Synlogic has a 1-year low of $5.75 and a 1-year high of $14.59. The company has a market cap of $211.25 million, a PE ratio of -4.04 and a beta of 2.40. The company has a debt-to-equity ratio of 0.20, a quick ratio of 11.53 and a current ratio of 11.53.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new position in Synlogic in the third quarter valued at approximately $33,000. Bank of Montreal Can boosted its holdings in Synlogic by 5,743.1% in the first quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 12,520 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Synlogic in the first quarter valued at approximately $114,000. TIAA CREF Investment Management LLC acquired a new position in Synlogic in the third quarter valued at approximately $251,000. Finally, Teachers Advisors LLC acquired a new position in Synlogic in the third quarter valued at approximately $290,000. 81.32% of the stock is owned by hedge funds and other institutional investors.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Read More: Diversification Important in Investing

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.